AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03642977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real time PCR and RT-PCR for DNA and RNA viral species
Description: Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
Study NCT02095470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope
Description: newly developed innovatory device
Study NCT02095470 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: traditional laryngoscope
Description: traditional way for intubation
Study NCT03308344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
Study NCT02517931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphenopalatine Ganglion Block
Description: Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
Study NCT02517931 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
Study NCT01841879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Program
Description: Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced.
Study NCT01841879 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Intervention
Description: Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
Study NCT02601157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-months DAPT
Description: Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
Study NCT02601157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-year DAPT
Description: Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
Study NCT00737776 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT03113032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-SEC Pre-Surgical Care
Description: The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
Study NCT03113032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal pre-surgical care
Description: Routine pre-surgical care
Study NCT04055675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine dipstick test
Description: A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
Study NCT03188159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
Study NCT01503008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus Sustained Behavior Change system
Description: The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
Study NCT01503008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Description: Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
Study NCT04474678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: My Logbook! - I know my way around!
Description: Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment.
Study NCT05224115 — intervention group
Intervention type: OTHER
Intervention: [11C]CHDI-00485180-R
Description: Mutant huntingtin aggregate binding PET radioligand.
Study NCT05224115 — intervention group
Intervention type: OTHER
Intervention: [11C]CHDI-00485626
Description: Mutant huntingtin aggregate binding PET radioligand.
Study NCT00516113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
Study NCT00516113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paroxetine
Description: Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
Study NCT02793726 — intervention group
Intervention type: PROCEDURE
Intervention: NMR
Description: NMR
Study NCT00522873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg NETA / 1.0mg E2 (Activella)
Description: One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Study NCT05464797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulp therapy
Description: partial or complete removal of inflamed pulp tissue
Study NCT02456155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placing nasal jejunal tube with ultrasound
Description: bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
Study NCT02456155 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placing nasal jejunal tube endoscopically
Study NCT01904409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01904409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 40 mg IR tablet
Study NCT01904409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 80 mg IR tablet
Study NCT01904409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 40 mg SER tablet
Study NCT01904409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 80 mg SER tablet
Study NCT01904409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 80mgIR/80mgSER tablet
Study NCT00659061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SPRINKLES
Description: Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services.
Study NCT00659061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
Study NCT00079040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00079040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00079040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00079040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03480152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Description: Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
Study NCT04312308 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: 1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional.
Study NCT01308736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
Study NCT01308736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
Study NCT04468061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Intravenous Infusion
Study NCT04468061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Infusion
Study NCT00101686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Bolus 5-FU/LV with Irinotecan
Description: Day 1 \& 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID \[two times a day\] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
Study NCT00101686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + bevacizumab
Description: Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID \[two times a day\] oral Every 2 weeks
Study NCT00101686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miFL + bevacizumab
Description: Day 1 Bevacizumab 7.5mg/kg IV \*over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID \[two times a day\] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID \[two times a day\] continues daily without interruption Every 3 weeks
Study NCT00101686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU/LV with Irinotecan
Description: Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID \[two times a day\](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
Study NCT00101686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Capecitabine with Irinotecan
Description: Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID \[two times a day\] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
Study NCT02903160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg PO daily
Study NCT02903160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO twice a day
Study NCT02903160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride
Description: 50 kBq/kg IV monthly
Study NCT02903160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: 25 mg/m2 IV every 3 weeks
Study NCT02903160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 IV every 3 weeks
Study NCT02903160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg PO daily
Study NCT01889875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Grazax 75,000 SQ-T Phleum pratense
Study NCT01889875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK AluTard 225 Phleum pratense
Study NCT02970981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02970981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT00523757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Study NCT00523757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01754974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a
Study NCT01754974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01754974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01754974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Study NCT03880058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLI-F06
Description: Active treatment
Study NCT03880058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formulation buffer
Description: Placebo treatment
Study NCT03018236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol N-acetylcysteine
Description: 1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
Study NCT03018236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Placebo
Description: Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
Study NCT03018236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine N-acetylcysteine
Description: 1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
Study NCT03018236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine Placebo
Description: Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
Study NCT03142529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colon lotion
Description: The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
Study NCT01475435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non- surgical periodontal treatment
Description: scaling and root planning
Study NCT01475435 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prophylaxis
Description: Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
Study NCT01682408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Description: 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Study NCT01682408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
Description: 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
Study NCT01682408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
Description: 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
Study NCT01682408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
Description: 1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
Study NCT01682408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150 mg ranitidine
Study NCT00763113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard PS Knee
Description: Vanguard PS Knee
Study NCT00763113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard CR Knee
Description: Vanguard CR Knee
Study NCT02977000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
Study NCT02920892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: 12.5 mg - 100 mg oral suspension (liquid)
Study NCT02920892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension (liquid)